XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$4.0m

XORTX Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

XORTX Therapeutics has a total shareholder equity of $2.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $3.9M and $1.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$2.30m
EquityUS$2.13m
Total liabilitiesUS$1.72m
Total assetsUS$3.85m

Recent financial health updates

Recent updates

XORTX completes positive pre-phase 3 meeting with the FDA

Sep 19

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Aug 22

XORTX jumps over 100% after early encouraging data for rare disease therapy

Jul 13

Financial Position Analysis

Short Term Liabilities: XRTX's short term assets ($2.4M) exceed its short term liabilities ($326.3K).

Long Term Liabilities: XRTX's short term assets ($2.4M) exceed its long term liabilities ($1.4M).


Debt to Equity History and Analysis

Debt Level: XRTX is debt free.

Reducing Debt: XRTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XRTX has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: XRTX is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies